Posted in M&A / Deals Update: Lilly makes $7bn bid for in vivo CAR-T firm Kelonia April 20, 2026 Pharmaphorum Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped. M&A / DealsOncologyRead full story